Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RVA
|
|||
| Former ID |
DIB000432
|
|||
| Drug Name |
CFG920
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0] | Phase 1/2 | [1] | |
| Company |
Novartis pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H13ClN4O
|
|||
| Canonical SMILES |
CC1=C(C=NC=C1)N2CCN(C2=O)C3=CC(=NC=C3)Cl
|
|||
| InChI |
1S/C14H13ClN4O/c1-10-2-4-16-9-12(10)19-7-6-18(14(19)20)11-3-5-17-13(15)8-11/h2-5,8-9H,6-7H2,1H3
|
|||
| InChIKey |
ZVIFCOOHWGNPHJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1260006-20-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Steroid 17-alpha-monooxygenase (S17AH) | Target Info | Inhibitor | [1] |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Glucocorticoid biosynthesis | ||||
| Androgen biosynthesis | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Ovarian steroidogenesis | ||||
| Prolactin signaling pathway | ||||
| Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
| Steroidogenesis | ||||
| Reactome | Androgen biosynthesis | |||
| Glucocorticoid biosynthesis | ||||
| Endogenous sterols | ||||
| WikiPathways | Metapathway biotransformation | |||
| Steroid Biosynthesis | ||||
| Oxidation by Cytochrome P450 | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| Glucocorticoid & Mineralcorticoid Metabolism | ||||
| Prostate Cancer | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.